 |
Selective outcome reporting, lack of full data publication and inappropriate analyses could be to blame Related items from OnMedica Are industry ‘supertrialists’ imbalancing diabetes research? BMJ questions trial evidence for rivaroxaban Database of pharmaceutical industry payments to doctors goes live GPs will have to declare gifts and hospitality Conflicted |
Wednesday, 18 January 2017
Financial ties between researchers and drug industry linked to positive trial results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment